Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rosa Maria Diaz

Showing results (21-30 of 44) with videos related to

Pageof 5
Sort By:
Cancer Research|December 20, 2007
Induction of hsp70-mediated Th17 autoimmunity can be exploited as immunotherapy for metastatic prostate cancerTimothy Kottke, Luis Sanchez-Perez, Rosa Maria Diaz, et al.
Cancer Research|September 24, 2009
Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesotheliomaCandice L Willmon, Vassiliki Saloura, Zvi G Fridlender, et al.
The Journal of Clinical Investigation|April 6, 2010
Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in miceTimothy Kottke, Geoff Hall, Jose Pulido, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 28, 2015
Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune ResponsesKarishma Rajani, Christopher Parrish, Timothy Kottke, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 24, 2008
Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virusTimothy Kottke, Feorillo Galivo, Phonphimon Wongthida, et al.
Cancer Research|June 18, 2003
Pharmacologically regulated production of targeted retrovirus from T cells for systemic antitumor gene therapyMarka Crittenden, Michael Gough, John Chester, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 22, 2025
Exploiting viral infection/vaccination to focus high-affinity T cell populations into tumors using oncolytic viro-immunotherapyAlexa Veliz Rios, Muriel Metko, Jason Tonne, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 9, 2017
Treg Depletion-enhanced IL-2 Treatment Facilitates Therapy of Established Tumors Using Systemically Delivered Oncolytic VirusTimothy Kottke, Feorillo Galivo, Phonphimon Wongthida, et al.
Nature Biotechnology|March 20, 2012
Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanomaJose Pulido, Timothy Kottke, Jill Thompson, et al.
Nature Biotechnology|August 10, 2004
A simple method to cure established tumors by inflammatory killing of normal cellsGregory A Daniels, Luis Sanchez-Perez, Rosa Maria Diaz, et al.
Pageof 5

Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
Cancer Research|December 20, 2007
Induction of hsp70-mediated Th17 autoimmunity can be exploited as immunotherapy for metastatic prostate cancerTimothy Kottke, Luis Sanchez-Perez, Rosa Maria Diaz, et al.
Cancer Research|September 24, 2009
Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesotheliomaCandice L Willmon, Vassiliki Saloura, Zvi G Fridlender, et al.
The Journal of Clinical Investigation|April 6, 2010
Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in miceTimothy Kottke, Geoff Hall, Jose Pulido, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 28, 2015
Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune ResponsesKarishma Rajani, Christopher Parrish, Timothy Kottke, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 24, 2008
Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virusTimothy Kottke, Feorillo Galivo, Phonphimon Wongthida, et al.
Cancer Research|June 18, 2003
Pharmacologically regulated production of targeted retrovirus from T cells for systemic antitumor gene therapyMarka Crittenden, Michael Gough, John Chester, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 22, 2025
Exploiting viral infection/vaccination to focus high-affinity T cell populations into tumors using oncolytic viro-immunotherapyAlexa Veliz Rios, Muriel Metko, Jason Tonne, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 9, 2017
Treg Depletion-enhanced IL-2 Treatment Facilitates Therapy of Established Tumors Using Systemically Delivered Oncolytic VirusTimothy Kottke, Feorillo Galivo, Phonphimon Wongthida, et al.
Nature Biotechnology|March 20, 2012
Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanomaJose Pulido, Timothy Kottke, Jill Thompson, et al.
Nature Biotechnology|August 10, 2004
A simple method to cure established tumors by inflammatory killing of normal cellsGregory A Daniels, Luis Sanchez-Perez, Rosa Maria Diaz, et al.
Pageof 5